Holen Sie sich die Stockscreener-App
0.9999
3.80%
0.0366
Handel nachbörslich:
1.05
0.0501
+5.01%
Schlusskurs vom Vortag:
$0.9633
Offen:
$0.9701
24-Stunden-Volumen:
96,080
Relative Volume:
0.96
Marktkapitalisierung:
$4.91M
Einnahmen:
$29.57M
Nettoeinkommen (Verlust:
$-34.68M
KGV:
-0.00141
EPS:
-708.7214
Netto-Cashflow:
$-7.58M
1W Leistung:
-20.96%
1M Leistung:
-66.78%
6M Leistung:
-95.54%
1J Leistung:
-98.60%
1-Tages-Spanne:
$0.91
$1.0199
1-Wochen-Bereich:
$0.91
$1.3596
52-Wochen-Spanne:
$0.91
$84.32
Jaguar Health Inc Stock (JAGX) Company Profile
Firmenname
Jaguar Health Inc
Sektor
Branche
Telefon
415-371-8300
Adresse
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
0.9999 | 4.73M | 29.57M | -34.68M | -7.58M | -708.72 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-07-11 | Eingeleitet | Rodman & Renshaw | Buy |
Jaguar Health Inc Aktie (JAGX) Neueste Nachrichten
Jaguar Health Inc (JAGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jaguar Health Inc (JAGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jaguar Health, Inc. SEC Filing (Jul 27, 2026) - Stock Titan
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID) - ACCESS Newswire
TradingKey - TradingKey
Jaguar Health (NASDAQ: JAGX) puts major dilution and incentive plan votes to investors - Stock Titan
Jaguar Health Inc (JAGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jaguar Health (JAGX) Secures Compassionate Use for Crofelemer in EU - GuruFocus
Jaguar Reports Up to 48% Lower Weekly Support in One MVID Patient - Stock Titan
Jaguar Health (JAGX) Registration filing Summary - Quartr
Jaguar Health Company Profile & Introduction - Moomoo
JAGUAR HEALTH INC (JAGX) Stock Chart - ChartMill
Form S-1 Jaguar Health Inc For: 16 July By Investing.com - Investing.com South Africa
Enterprise value to EBIT forward of Jaguar Health, Inc. – FWB:1JA1 - TradingView
Jaguar Health (NASDAQ: JAGX) plans 5.5M-share resale registration - Stock Titan
Jaguar Health (NASDAQ: JAGX) details 40.8M-share, $40M equity line - Stock Titan
Jaguar Health | S-1: General form for registration of securities under the Securities Act of 1933 - Moomoo
Jaguar Health Napo And Alivus Enter New Manufacturing And Supply Agreement For CrofelemerSEC Filing - TradingView
Jaguar Health Extends Crofelemer Supply With Alivus Through 2029, Adds Minimum Purchase Commitments - TradingView
Jaguar Health (NASDAQ: JAGX) signs new crofelemer manufacturing pact - Stock Titan
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - ACCESS Newswire
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program - ACCESS Newswire
MSN Money - MSN
Jaguar Health (JAGX) Lytham Partners Fall 2025 Investor Conference Summary - Quartr
Jaguar Health (JAGX) Proxy filing Summary - Quartr
Price to book forward of Jaguar Health, Inc. – FWB:1JA1 - TradingView
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health - ACCESS Newswire
Jaguar Health stock and its path in specialty pharma. Investors weigh volatile moves - ad-hoc-news.de
Jaguar Health (JAGX) Slides 7.6% as Selling Pressure Tests Key Support ZoneCalendar Spread Trade - dars.gov.et
JAGXJaguar Health Inc Latest SEC Filings - Finviz
Jaguar Health to Present at Lytham Partners Fall 2022 Investor Conference on September 28th and at Ladenburg Thalmann 2022 Healthcare Conference on September 29th - ACCESS Newswire
Jaguar Health, Inc. Files 8-K Report on July 1, 2026 – Key Company Information & SEC Disclosure Details - Minichart
Jaguar Health Inc. Q1 2026 Earnings: EPS Falls Far Below Estimates, Stock Edges Higher Despite No Revenue - dars.gov.et
Enterprise value to revenue forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Jaguar Health Completes Conversion of Series O Preferred - TipRanks
Jaguar Health (JAGX) completes Series O preferred stock conversion to common shares - Stock Titan
Jaguar Health Inc. (JAGX) Holds Steady at $2.96 as Stock Consolidates Near Key LevelsTriple EMA - dars.gov.et
Jaguar Health (JAGX) Showcases Crofelemer Data at ESPGHAN Conference - GuruFocus
Jaguar Health reports crofelemer data for rare pediatric diseases By Investing.com - Investing.com Nigeria
Jaguar Health reports crofelemer data for rare pediatric diseases - Investing.com
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF) - ACCESS Newswire
Jaguar Health says crofelemer cut one child's support needs by 48% - Stock Titan
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders - ACCESS Newswire
Enterprise value to EBIT forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
JAGX Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock Rallies Despite SurpriseShare Dilution Risk - dars.gov.et
Price to earnings forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Price to earnings forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Price to book forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Enterprise value to revenue forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Jaguar Health shares after reverse split, small-cap biotech stock in the OTC market spotlight - AD HOC NEWS
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing - GlobeNewswire Inc.
Finanzdaten der Jaguar Health Inc-Aktie (JAGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):